Inaba N, Negishi Y, Fukasawa I, Okajima Y, Ota Y, Tanaka K, Matsui H, Iwasaki H, Sudo H, Tanaka N
Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, Tochigi, Japan.
Tumour Biol. 1995;16(6):345-52. doi: 10.1159/000217951.
We measured serum cytokeratin fragment 21-1 (CYFRA 21-1) levels by a solid-phase immunoradiometric assay in 102 healthy Japanese women, and set the reference value at 1.9 ng/ml (mean +2 SD of the serum levels based on a linear distribution). Pretreatment serum CYFRA 21-1 levels were also analyzed in 235 women with benign (n = 94) or malignant (n = 141) gynecologic disease, and were compared with the serum levels of CA 125 and SCC. The respective positivity rates for CYFRA 21-1 and CA 125 were 64.0 and 77.2% in ovarian malignancy, while they were 4.2 and 30.8% in benign ovarian masses. CYFRA 21-1 had an accuracy of 61.3% in diagnosing ovarian malignancy, which was higher than that of CA 125 (53.4%). The positive predictive value of CYFRA 21-1 for ovarian malignancy reached 94.1%, which was significantly (p < 0.005) higher than that of CA 125 (68.8%). These findings indicate the potential usefulness of CYFRA 21-1 as a tumor marker for ovarian malignancy. In addition, the positivity rates fo CYFRA 21-1 in cervical cancer (51.2%) and endometrial cancer (52.2%) were also similar to the respective rates for SCC and CA 125, which suggests that CYFRA 21-1 seems to be a general tumor marker for gynecologic malignancy.
我们采用固相免疫放射分析方法测定了102名健康日本女性的血清细胞角蛋白片段21-1（CYFRA 21-1）水平，并将参考值设定为1.9 ng/ml（基于线性分布的血清水平均值+2标准差）。我们还分析了235例患有良性（n = 94）或恶性（n = 141）妇科疾病女性的治疗前血清CYFRA 21-1水平，并与CA 125和鳞状细胞癌抗原（SCC）的血清水平进行比较。在卵巢恶性肿瘤中，CYFRA 21-1和CA 125的各自阳性率分别为64.0%和77.2%，而在良性卵巢肿块中分别为4.2%和30.8%。CYFRA 21-1诊断卵巢恶性肿瘤的准确率为61.3%，高于CA 125（53.4%）。CYFRA 21-1对卵巢恶性肿瘤的阳性预测值达到94.1%，显著高于CA 125（68.8%）（p < 0.005）。这些发现表明CYFRA 21-1作为卵巢恶性肿瘤肿瘤标志物具有潜在的应用价值。此外，CYFRA 21-1在宫颈癌（51.2%）和子宫内膜癌（52.2%）中的阳性率也分别与SCC和CA 125的阳性率相似，这表明CYFRA 21-1似乎是妇科恶性肿瘤的一种通用肿瘤标志物。
